Active Biotech Completes Patient Enrollment to ANYARA Phase III Clinical Trial
This pivotal Phase III study evaluates the efficacy and safety of ANYARA in combination with interferon-alfa compared to interferon-alfa alone, in patients with advanced renal cell cancer. The primary clinical efficacy parameter is overall survival. Final survival data for ANYARA will be analyzed after 384 events and the current estimate is that these will be presented by the end of 2010/beginning of 2011. [more...]
|
|
|
